KRAS and BRAF Mutation Screening in Metastatic Colorectal Cancer Costly in Relation to Benefits, National Cancer Institute Study
Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according to a new study published on November 28 in the Journal of the National Cancer Institute.